drugset
drugset / Trial / NCT06465472

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

NCT06465472 ↗

Phase 3 Not yet recruiting 42 enrolled Biocodex Exystat · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3.

Timeline

Start
2024-08
Primary completion
2030-08
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Stiripentol Small molecule 50 mg/kg Oral

Indications

primary hyperoxaluria type 1 primary hyperoxaluria type 2 primary hyperoxaluria type 3